By using three independent analysis (anti-Aβ immunostaining, anti-Aβ ELISA, and ThS staining), we observed that the ASR1-treated AD brain homogenate significantly reduced its ability to induce Aβ aggregation in the hippocampus of challenged animals. The gene discussed is FAU; the disease is Alzheimer disease.